Essa Pharma downgraded to Perform from Outperform at Oppenheimer
The Fly

Essa Pharma downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Leland Gershell downgraded Essa Pharma (EPIX) to Perform from Outperform without a price target The company announced that it will discontinue all masofaniten development following a prespecified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study, the analyst tells investors in a research note. The firm awaits details as Essa moves to a strategic process in which it will explore options that can maximize shareholder value.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App